Categories: Gastrointestinal diseases, Metabolic diseases, Muscle diseases, Rare diseases

Aliases & Classifications for Gastroparesis

MalaCards integrated aliases for Gastroparesis:

Name: Gastroparesis 12 20 54 44 15 17 70
Delayed Gastric Emptying 20
Gastroparesis Syndrome 12
Gastroparalysis 12
Gastric Atonia 12


External Ids:

Disease Ontology 12 DOID:11914
ICD9CM 34 536.3
MeSH 44 D018589
NCIt 50 C80512
SNOMED-CT 67 235675006
ICD10 32 K31.84
UMLS 70 C0152020

Summaries for Gastroparesis

GARD : 20 Gastroparesis, or delayed gastric emptying, is a disorder where the food does not move or moves very slowly from the stomach to the small intestine. In gastroparesis, the muscles of the stomach do not work well and digestion takes an abnormally long time. Symptoms of gastroparesis include bloating, nausea, vomiting, weight loss due to poor absorption of nutrients, early fullness while eating meals, heartburn, and abdominal pain. Complications can occur including dehydration, electrolyte abnormalities, blood sugar abnormalities, malnutrition, vitamin deficiencies, stomach ulcers, gastroesophageal reflux, esophagitis, small bowel bacterial overgrowth, and metabolic bone disease. In rare cases, food that is poorly digested can collect in the stomach and form a bezoar, a mass of undigested material that can cause a blockage in the gastrointestinal tract. Gastroparesis is more common in people with diabetes and those who have had recent stomach or intestinal surgery. Other causes include infections, hormonal disorders like hypothyroidism, connective tissue disorders like scleroderma, autoimmune conditions, neuromuscular diseases, psychological conditions, and eating disorders. In some cases, the cause is not known (idiopathic). Diagnosis is made on the basis of a radiographic gastric emptying test. Treatment may include dietary modifications such as adjusting the timing and size of meals, consuming more liquid-based meals, or avoiding foods that are more difficult to digest (such as fatty foods, or foods with too much fiber). Other treatments may include endoscopic procedures to break the bezoar apart and remove it, feeding tubes, surgery, placement of an electrical stimulator, and medication such as metoclopramide, domperidone, erythromycin and cisapride. With proper management many people with gastroparesis can live a relatively normal life. However, others may not tolerate treatment and may experience significant complications, a decreased quality of life, and reduced survival.

MalaCards based summary : Gastroparesis, also known as delayed gastric emptying, is related to idiopathic gastroparesis and autonomic neuropathy, and has symptoms including ophthalmoplegia, hemiplegia and signs and symptoms, digestive. An important gene associated with Gastroparesis is MLN (Motilin), and among its related pathways/superpathways are Peptide ligand-binding receptors and Circadian entrainment. The drugs Sodium citrate and Esomeprazole have been mentioned in the context of this disorder. Affiliated tissues include pancreas, small intestine and smooth muscle, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 73 Gastroparesis (gastro- from Ancient Greek γαστήρ - gaster, "stomach"; and -paresis, πάρεσις - "partial... more...

Related Diseases for Gastroparesis

Diseases related to Gastroparesis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 400)
# Related Disease Score Top Affiliating Genes
1 idiopathic gastroparesis 31.5 MRC1 HMOX1 GIP GHSR GHRL
2 autonomic neuropathy 31.2 MLN GAST CCK
3 gastroesophageal reflux 30.8 MLN GHRL GAST CCK
4 pylorospasm 30.7 MLNR MLN
5 diabetic autonomic neuropathy 30.7 MLNR MLN GAST
6 tardive dyskinesia 30.6 DRD2 CYP2D6
7 rumination disorder 30.6 MLNR MLN
8 intestinal obstruction 30.3 MLN GHRL ANO1
9 eating disorder 30.3 GHRL DRD2 CCK
10 bulimia nervosa 30.3 GHRL DRD2 CCK
11 intestinal pseudo-obstruction 30.3 SST MLNR MLN
12 volvulus of midgut 30.3 SST MLNR MLN
13 gastritis 30.2 SST SCT GHRL GAST
14 irritable bowel syndrome 30.1 SST MLN GHRL CCK
15 bilirubin metabolic disorder 30.1 HMOX1 CYP3A4 CYP2D6 ABCB1
16 gastrointestinal system disease 30.1 MLN GHRL GAST CCK
17 atrophic gastritis 30.0 SST GHRL GAST
18 hyperglycemia 30.0 SST GIP GHRL CCK
19 peptic esophagitis 30.0 MLN GAST
20 hernia, hiatus 30.0 MLN GHRL GAST
21 pyloric stenosis 29.9 SST NOS1 MLN GAST
22 bile reflux 29.9 SCT MLN GAST CCK
23 biliary dyskinesia 29.9 SST SCT CCK
24 small cell cancer of the lung 29.8 SST GAST CCK
25 peptic ulcer disease 29.7 SST SCT GHRL GAST
26 gallbladder disease 29.7 SST MLN CCK
27 gilbert syndrome 29.7 HMOX1 CYP3A4 CYP2D6
28 cholelithiasis 29.6 SST GAST CCK
29 sexual disorder 29.6 NOS1 CYP3A4 CYP2D6
30 ileus 29.5 SST MLN GHSR GHRL CCK
31 celiac disease 1 29.5 SCT GHRL GAST CCK
32 alcohol dependence 29.5 TH GHRL DRD2 CCK
33 duodenal ulcer 29.4 SST SCT MLN GAST CCK
34 duodenogastric reflux 29.2 SST SCT MLN GAST CCK
35 migraine with or without aura 1 29.2 SCT NOS1 DRD2 CYP3A4 CYP2D6 CCK
36 acute pancreatitis 29.1 SST SCT CCK
37 dumping syndrome 29.1 SST SCT MLN GIP GHRL GAST
38 diarrhea 29.0 SST SCT MLN GAST CYP3A4 CYP2D6
39 anxiety 28.8 TH GHRL DRD2 CYP3A4 CYP2D6 CCK
40 constipation 28.5 TH SST NOS1 MLNR MLN GHRL
41 body mass index quantitative trait locus 11 28.3 NOS1 KCNH2 HMOX1 GIP GHSR GHRL
42 type 2 diabetes mellitus 28.2 SST SCT NOS1 HMOX1 GIP GHRL
43 diabetes mellitus 27.3 TH SST SCT NOS1 MLN HMOX1
44 brittle diabetes 11.0
45 stomach disease 11.0
46 galactorrhea 10.4 DRD2 CYP2D6
47 neurogenic bowel 10.4 MLN GAST
48 acute diffuse nephritis 10.3 KCNH2 ABCB1
49 type 1 diabetes mellitus 10.3
50 postcholecystectomy syndrome 10.3 MLN GAST CCK

Graphical network of the top 20 diseases related to Gastroparesis:

Diseases related to Gastroparesis

Symptoms & Phenotypes for Gastroparesis

UMLS symptoms related to Gastroparesis:

ophthalmoplegia; hemiplegia; signs and symptoms, digestive; lassitude; persistent vomiting

GenomeRNAi Phenotypes related to Gastroparesis according to GeneCards Suite gene sharing:

# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00240-S-1 9.68 SST
2 Decreased viability GR00249-S 9.68 ABCB1 ANO1 GHRL GHSR MLN NOS1
3 Decreased viability GR00381-A-1 9.68 CYP2D6 GHSR MLN MLNR SCT
4 Decreased viability GR00381-A-2 9.68 GHSR
5 Decreased viability GR00381-A-3 9.68 GHSR MLN
6 Decreased viability GR00386-A-1 9.68 CCK MLN
7 Decreased viability GR00402-S-2 9.68 ABCB1 ADRA1D CYP2D6 GHSR MLN SCT

MGI Mouse Phenotypes related to Gastroparesis:

# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.81 ABCB1 ANO1 DRD2 GAST GHRL GHSR
2 homeostasis/metabolism MP:0005376 9.8 ABCB1 ANO1 CCK DRD2 GAST GHRL
3 no phenotypic analysis MP:0003012 9.17 ABCB1 CCK DRD2 GHSR NOS1 SST

Drugs & Therapeutics for Gastroparesis

Drugs for Gastroparesis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 154)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Sodium citrate Approved, Investigational Phase 4 68-04-2
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
Cisapride Approved, Investigational, Withdrawn Phase 4 81098-60-4 2769 6917698
Tegaserod Approved, Investigational, Withdrawn Phase 4 145158-71-0, 189188-57-6 122724
Haloperidol Approved Phase 4 52-86-8 3559
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
Mosapride Investigational Phase 4 112885-41-3
10 Citrate Phase 4
11 Proton Pump Inhibitors Phase 4
12 Gastrointestinal Agents Phase 4
13 Antacids Phase 4
14 Anti-Ulcer Agents Phase 4
15 Dopamine Agents Phase 4
16 Antiemetics Phase 4
17 Dopamine Antagonists Phase 4
18 Neurotransmitter Agents Phase 4
19 Psychotropic Drugs Phase 4
20 Serotonin Receptor Agonists Phase 4
21 Antipsychotic Agents Phase 4
22 Opiate Alkaloids Phase 4
23 Haloperidol decanoate Phase 4
24 Analgesics Phase 4
Acetylcholine Approved, Investigational Phase 3 51-84-3 187
Prucalopride Approved Phase 2, Phase 3 179474-81-8
Nortriptyline Approved Phase 3 72-69-5 4543
Domperidone Approved, Investigational, Vet_approved Phase 3 57808-66-9 3151
29 Cholinergic Agents Phase 3
30 Antidepressive Agents, Tricyclic Phase 3
31 Adrenergic Agents Phase 3
32 Antidepressive Agents Phase 3
Substance P Phase 3 33507-63-0 44359816
34 neurokinin A Phase 3
Lixisenatide Approved Phase 1, Phase 2 320367-13-3
Aprepitant Approved, Investigational Phase 2 170729-80-3 151165 6918365
Fosaprepitant Approved Phase 2 172673-20-0 219090
Levodopa Approved Phase 2 59-92-7 6047
Buspirone Approved, Investigational Phase 2 36505-84-7 2477
Rifaximin Approved, Investigational Phase 2 80621-81-4 6436173 46783403
Erythromycin Approved, Investigational, Vet_approved Phase 2 114-07-8 12560
Metoclopramide Approved, Investigational Phase 2 364-62-5 4168
Azithromycin Approved Phase 2 83905-01-5 55185 447043
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
Histamine Approved, Investigational Phase 2 51-45-6, 75614-87-8 774
Promethazine Approved, Investigational Phase 2 60-87-7 4927
Loperamide Approved Phase 2 53179-11-6 3955
Bismuth subsalicylate Approved, Vet_approved Phase 2 14882-18-9 53629521
Methylnaltrexone Approved Phase 2 916055-93-1, 83387-25-1 6603824
Acetaminophen Approved Phase 2 103-90-2 1983

Interventional clinical trials:

(show top 50) (show all 221)
# Name Status NCT ID Phase Drugs
1 Prucalopride Versus Placebo in Functional Dyspepsia With Delayed Gastric Emptying Unknown status NCT02510976 Phase 4 prucalopride;placebo
2 Effects and Mechanism of Mosapride Citrate on Diabetic Gastroparesis Unknown status NCT02264587 Phase 4 Mosapride;domperidone
3 Effect of Proton Pump Inhibitor on Gastric Emptying and Satiety Function in Patients With Functional Dyspepsia Completed NCT00951431 Phase 4 Esomeprazole;Placebo
4 Pharmacokinetics of Immediate-Release vs. Delayed-Release Omeprazole in Patients With Heartburn Associated With Gastroparesis Completed NCT00492622 Phase 4 Immediate-release omeprazole;Delayed-release omeprazole
5 Enterra Therapy Gastric Stimulation System Terminated NCT00556166 Phase 4
6 Double-Blind, Randomized, Placebo-Controlled Trial To Assess Efficacy And Safety Of R051619 (Cisapride 10 mg q.i.d.) Versus Placebo For The Improvement Of Symptoms Associated With Exacerbations Of Idiopathic Gastroparesis, After Failure Of Other Treatment Options Terminated NCT01281540 Phase 4 Cisapride;Placebo
7 Double-Blind, Randomized, Placebo-Controlled Trial to Assess Efficacy and Safety of R051619 (Cisapride 10 mg Q.I.D.) Versus Placebo for the Improvement of Symptoms Associated With Exacerbations of Gastroparesis, After Failure of Other Treatments, in Patients With Diabetes Mellitus Terminated NCT01286090 Phase 4 Cisapride;Placebo
8 An Open-label Pilot Trial to Assess the Effect of Tegaserod on Improvement of Gastric Emptying in Patients With Diabetic Gastroparesis and Upper Gastrointestinal Symptoms Terminated NCT00390975 Phase 4 Tegaserod
9 Haloperidol vs Conventional Therapy for Gastroparesis Terminated NCT02057549 Phase 4 Haloperidol;Conventional Therapy
10 Daily Tadalafil and Gastric Emptying Time in Diabetic Gastroparesis Withdrawn NCT01326117 Phase 4 tadalafil
11 A Randomized Controlled Trial of Gastric Meal With and Without Prior Jejunal Feeding on GI Symptoms and Response in Patients With Diabetic Gastro-enteropathy, Diabetic Controls and Healthy Volunteers Withdrawn NCT00944593 Phase 4
12 Effect of Electroacupuncture in Diabetic Patients With Gastroparesis Unknown status NCT00227383 Phase 3
13 Comparison Between Antecolic and Retrocolic Gastrointestinal Reconstruction in Delayed Gastric Emptying After Pancreaticoduodenectomy: A Prospective Randomized Controlled Multicenter Trial Unknown status NCT01460550 Phase 3
14 Per-oral Endoscopy Pyloromyotomy (G-POEM) in the Treatment of Refractory Diabetic Gastroparesis : Prospective Evaluation of Efficacy Unknown status NCT02927886 Phase 3
15 Sancuso® in Patients With Nausea and/or Vomiting From Gastroparesis: An Open Label Study. Unknown status NCT01989221 Phase 3 Sancuso®
16 Nortriptyline for Idiopathic Gastroparesis: A Multicenter, Randomized, Double-Masked, Placebo-Controlled Trial (NORIG) Completed NCT00765895 Phase 3 Nortriptyline Hydrochloride;Placebo (for nortriptyline)
17 Prucalopride Versus Placebo in Gastroparesis: Randomized Placebo-controlled Crossover Trial Completed NCT02031081 Phase 2, Phase 3 Prucalopride;Placebo
18 Phase 3 Companion Study of Intranasal Metoclopramide in Men With Symptomatic Diabetic Gastroparesis Completed NCT02025751 Phase 3 Metoclopramide Nasal Spray;Placebo Nasal Spray
19 Phase 3 Study of Intranasal Metoclopramide in Women With Symptomatic Diabetic Gastroparesis Completed NCT02025725 Phase 3 Metoclopramide Nasal Spray;Placebo Nasal Spray
20 Double-Blind Placebo-Controlled Cross-Over Design With Wash-Out for Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis Completed NCT00432835 Phase 3
21 VP-VLY-686-3301: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Iii Study To Assess The Efficacy Of Tradipitant In Relieving Symptoms Of Gastroparesis Recruiting NCT04028492 Phase 3 Tradipitant;Placebo
22 Dynamic Positron Emission Tomography Imaging With 11C-ER176 to Delineate Macrophage Activation in Diabetic Gastroparesis Recruiting NCT04762719 Phase 2, Phase 3 PET/CT Scan with 11C-ER176
23 Treatment Protocol for the Compassionate Use of Domperidone Recruiting NCT01696734 Phase 3 Domperidone
24 A Randomized, Placebo/Sham-Controlled, Double-Blind Crossover Study to Assess the Efficacy of Acupuncture in the Treatment of Diabetic Gastroparesis. Suspended NCT00470795 Phase 3
25 Open-label Extension Study of Relamorelin for the Treatment of Diabetic Gastroparesis Terminated NCT03786380 Phase 3 Relamorelin 10 μg
26 A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis Terminated NCT03426345 Phase 3 Relamorelin;Placebo
27 A 46-week, Double-blind, Placebo-controlled, Phase 3 Study With a 6-week Randomized-withdrawal Period to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis Terminated NCT03420781 Phase 3 Relamorelin;Placebo
28 A 52-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis Terminated NCT03383146 Phase 3 Relamorelin;Placebo
29 A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis Terminated NCT03285308 Phase 3 Relamorelin;Placebo
30 Monitoring Study for the Use of Gastroparesis for Patient Who Have Failed Standard Therapy Withdrawn NCT01378884 Phase 3 Domperidone
31 Phase III Study on Comparison for Bile Reflux and Gastric Stasis in Patients With Gastric Cancer After Distal Gastrectomy Withdrawn NCT00622804 Phase 3
32 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Proof of Concept Study to Assess the Efficacy of VLY-686 (Tradipitant) in Relieving Symptoms of Gastroparesis Unknown status NCT02970968 Phase 2 VLY-686 (Tradipitant)
33 Effects of Lixisenatide on Gastric Emptying, Glycaemia and 'Postprandial' Blood Pressure in Type 2 Diabetes and Healthy Subjects. Unknown status NCT02308254 Phase 1, Phase 2 Lixisenatide;Placebo
34 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of Once-Daily Administrations of TZP-102 for the Treatment of Symptoms Associated With Diabetic Gastroparesis Completed NCT01452815 Phase 2 Placebo;10mg TZP-102;20mg TZP-102
35 Acupuncture Treatment for Gastroparesis: a Pilot Study Completed NCT01643577 Phase 1, Phase 2
36 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Evaluation of the Safety and Efficacy of Once-Daily Administrations of TZP 102 for the Treatment of Symptomatic Gastroparesis in Patients With Diabetes Mellitus Completed NCT00889486 Phase 2 TZP-102;Placebo
37 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-ranging Study to Assess the Efficacy and Safety of TZP-101 When Administered as a 30 Minute I.V. Infusion to Subjects With Severe Gastroparesis Due to Diabetes Mellitus Completed NCT00612014 Phase 2 5% dextrose in water;TZP-101;TZP-101;TZP-101;TZP-101;TZP-101
38 A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase II Study to Evaluate the Safety and Efficacy and Dose Response of 28 Days of Once-Daily Dosing of the Oral Motilin Receptor Agonist GSK962040, in Type I and II Diabetic Male and Female Subjects With Gastroparesis Completed NCT01262898 Phase 2 GSK962040 (5 mg tablet);GSK962040 (25 mg tablet);GSK962040 (125 mg tablet);Placebo
39 Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin: A Multicenter, Randomized, Double-Masked, Placebo-Controlled Trial Completed NCT01149369 Phase 2 Aprepitant;Placebo
40 A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis Completed NCT02210000 Phase 2 Placebo;Camicinal
41 A Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose Ranging Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric Emptying Completed NCT01602549 Phase 2 GSK962040 (25 mg tablet);Placebo
42 A Multi-center, Open-label Comparison Study of a 13C-uracil Breath Test Versus 99mTechnetium Sulfur Colloid Gastric Emptying Scintigraphy to Evaluate Normal, and Delayed Gastric Emptying Time in Dyspeptic Subjects Completed NCT01677338 Phase 2 13C-uracil;99mTc sulfur colloid
43 Pectin Start Early Enteral Nutritional Support in Critically Ill Patients Completed NCT02379624 Phase 1, Phase 2 pectin
44 A 2-Part, Randomized, Double Blind and Open-Label, Placebo and Active-Comparator Controlled Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics for TAK-906 in Subjects With Diabetes Mellitus and Gastroparesis or With Idiopathic Gastroparesis Completed NCT03268941 Phase 2 TAK-906 Maleate;Metaclopramide;TAK-906 Maleate Placebo
45 Comparing Treatment With Food of Small Particle Size and Food of Large Particle Size in Subjects With Diabetic Gastroparesis. Evaluation of Diagnostic Methods. Determination of the Motility of Gastric Emptying After Intervention Completed NCT01557296 Phase 2
46 A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of RM-131 Administered to Patients With Diabetic Gastroparesis Completed NCT01571297 Phase 2 RM-131;Placebo
47 Pilot Study to Evaluate Magnetic Marker Imaging on Diabetic Polyneuropathy and Gastroparesis Completed NCT01607684 Phase 2
48 A Multicenter, Double-Blind, Randomized Placebo-Controlled Phase II Study to Evaluate the Pharmacodynamics, Safety, Tolerability, and PK of Single Doses of the Oral Motilin Receptor Agonist GSK962040, in Type 1 Diabetic Male and Female Patients With Gastroparesis Completed NCT00861809 Phase 2 GSK962040 25 mg;Placebo;GSK962040 50 mg;GSK962040 1250 mg
49 A Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Dose-Ranging Clinical Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray Solution in Diabetic Subjects With Gastroparesis Completed NCT00845858 Phase 2 metoclopramide;Placebo
50 A Multicenter, Double-Blind, Randomized, Placebo- Controlled, Phase 2 Study to Evaluate Velusetrag Effects on Gastric Emptying in Subjects With Diabetic or Idiopathic Gastroparesis Completed NCT01718938 Phase 2 velusetrag dose 1;velusetrag dose 2;velusetrag dose 3;placebo

Search NIH Clinical Center for Gastroparesis

Inferred drug relations via UMLS 70 / NDF-RT 51 :

Metoclopramide Hydrochloride

Cochrane evidence based reviews: gastroparesis

Genetic Tests for Gastroparesis

Anatomical Context for Gastroparesis

MalaCards organs/tissues related to Gastroparesis:

Pancreas, Small Intestine, Smooth Muscle, Kidney, Lung, Pituitary, Spinal Cord

Publications for Gastroparesis

Articles related to Gastroparesis:

(show top 50) (show all 2717)
# Title Authors PMID Year
Gastroparesis: Quality of Life and Health Care Utilization. 61 20
27775961 2018
Psychological controversies in gastroparesis: A systematic review. 61 20
28275310 2017
Gastroparesis: A Review of Current Diagnosis and Treatment Options. 20 61
25874755 2015
Gastroparesis: approach, diagnostic evaluation, and management. 61 20
21329779 2011
Ghrelin and obestatin levels in type 2 diabetic patients with and without delayed gastric emptying. 61 54
19082715 2009
Postprandial secretion of ghrelin in hemodialysis patients with and without diabetic nephropathy. 61 54
19776684 2009
Actions and therapeutic pathways of ghrelin for gastrointestinal disorders. 61 54
19434096 2009
Ghrelin receptor agonist (TZP-101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis. 61 54
19298585 2009
Influence of ghrelin on the gastric accommodation reflex and on meal-induced satiety in man. 54 61
19210631 2009
No ghrelin response to oral glucose in diabetes mellitus with gastroparesis. 61 54
18946177 2009
Application of ghrelin to gastrointestinal diseases. 54 61
18821473 2008
Effects of oral mitemcinal (GM-611), erythromycin, EM-574 and cisapride on gastric emptying in conscious rhesus monkeys. 54 61
17934842 2008
Clinical trial: effect of mitemcinal (a motilin agonist) on gastric emptying in patients with gastroparesis - a randomized, multicentre, placebo-controlled study. 61 54
17894654 2007
Potential of ghrelin as a therapeutic approach for gastrointestinal motility disorders. 54 61
17011824 2006
Ghrelin stimulates gastric emptying and hunger in normal-weight humans. 61 54
16772353 2006
Abnormal ghrelin and pancreatic polypeptide responses in gastroparesis. 61 54
16868831 2006
Ghrelin gastrokinetic action in patients with neurogenic gastroparesis. 61 54
16426704 2006
[The effects of enteral nutrition vs parenteral nutrition on gastric motility and gastroenteric hormones after subtotal gastrectomy: a perspective randomized compared clinical trial]. 61 54
16836917 2006
Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses. 54 61
16492694 2006
Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study. 61 54
16085693 2005
Influence of ghrelin on gastric emptying and meal-related symptoms in idiopathic gastroparesis. 54 61
16225494 2005
Novel approaches to the treatment of nausea and vomiting. 61 54
10697661 1999
Comparison of metoclopramide and erythromycin in the treatment of diabetic gastroparesis. 61 54
8299441 1993
Erythromycin, motilin, and gastroparesis. 61 54
1464218 1992
Post-operative gastroparesis following carbohydrate loading in a diabetic patient. 61
33644283 2021
Mechanistic role of antioxidants in rescuing delayed gastric emptying in high fat diet induced diabetic female mice. 61
33761597 2021
Long-term Outcome of Gastric Per-Oral Endoscopic Pyloromyotomy in Treatment of Gastroparesis. 61
32450364 2021
A link between gastrointestinal disorders and migraine: Insights into the gut-brain connection. 61
33793965 2021
Safe passage: uncomplicated migration of a 20-mm lumen-apposing metal stent deployed across the pylorus for gastroparesis. 61
33129796 2021
The Surgeon's Role in Gastric Electrical Stimulation Therapy for Gastroparesis. 61
33236324 2021
Epidemiology of gastroparesis: important answers and still more questions. 61
32694176 2021
Meal-Induced Symptoms in Children with Dyspepsia-Relationships to Sex and the Presence of Gastroparesis. 61
33359472 2021
Pathophysiology of Gastroparesis Syndromes Includes Anatomic and Physiologic Abnormalities. 61
32328893 2021
Medical and surgical management of gastroparesis: a systematic review. 61
33722476 2021
What is Missing Before Gastric Peroral Endoscopic Myotomy Can Go Mainstream for Treatment of Gastroparesis? 61
32739570 2021
Velusetrag accelerates gastric emptying in subjects with gastroparesis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 study. 61
33811761 2021
Comment on: Medical and surgical management of gastroparesis: a systematic review. 61
33423963 2021
Epidemiology and outcomes of gastroparesis, as documented in general practice records, in the United Kingdom. 61
32493829 2021
[Related factors for bile duct infection after surgical treatment of biliary dilatation]. 61
33706446 2021
Comprehensive Analysis of Adverse Events Associated with Gastric Peroral Endoscopic Myotomy: An International Multicenter Study. 61
32328824 2021
Adrenal insufficiency misdiagnosed as diabetic gastroparesis. 61
33783713 2021
In-hospital mortality in gastroparesis population and its predictors: A United States-based population study. 61
33732881 2021
Controversies in Gastroparesis: Discussing the Sticky Points. 61
33767098 2021
Gastric per-oral endoscopic myotomy (G-POEM) for refractory gastroparesis: results from an international prospective trial. 61
33741641 2021
Selecting optimal patients with gastroparesis for G-POEM procedure. 61
33785556 2021
Metoclopramide nasal spray for management of symptoms of acute and recurrent diabetic gastroparesis in adults. 61
33739209 2021
Trends and Socioeconomic Health Outcomes of Cannabis Use Among Patients With Gastroparesis: A United States Nationwide Inpatient Sample Analysis. 61
33780213 2021
Pyloric dilation with the eosophgeal functional lumen imaging probe in gastroparesis improves gastric emptying, pyloric distensibility, and symptoms. 61
33771556 2021
Impact of Robotic Versus Laparoscopic Pyloroplasty on Short- and Long-term Outcomes in Patients with Gastroparesis. 61
33772401 2021
Gastroparesis secondary to pulmonary vein cryoablation: a factor to consider. 61
33222475 2021

Variations for Gastroparesis

Expression for Gastroparesis

Search GEO for disease gene expression data for Gastroparesis.

Pathways for Gastroparesis

Pathways related to Gastroparesis according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
3 12.37 KCNH2 CYP3A4 CYP2D6 ABCB1
Show member pathways
Show member pathways
11.84 CYP3A4 CYP2D6 ABCB1
Show member pathways
11.81 CYP3A4 CYP2D6 ABCB1
8 11.67 SCT CYP3A4 ABCB1
Show member pathways
11.48 CYP3A4 CYP2D6 ABCB1
Show member pathways
11.4 CYP3A4 CYP2D6 ABCB1
Show member pathways
11.32 CYP3A4 CYP2D6 ABCB1
Show member pathways
11.12 CYP3A4 CYP2D6 ABCB1
Show member pathways
11.08 CYP3A4 CYP2D6 ABCB1
14 10.83 CYP3A4 ABCB1
Show member pathways
10.78 CYP3A4 CYP2D6
16 10.74 CYP3A4 ABCB1
17 10.73 CYP2D6 ABCB1
18 10.72 CYP3A4 ABCB1
Show member pathways
10.57 CYP3A4 CYP2D6
20 10.51 CYP3A4 ABCB1
21 10.23 TH GHSR GHRL DRD2
22 9.98 SCT GAST CCK

GO Terms for Gastroparesis

Biological processes related to Gastroparesis according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 response to hypoxia GO:0001666 9.87 TH NOS1 HMOX1 DRD2
2 memory GO:0007613 9.81 TH GIP CCK
3 response to hormone GO:0009725 9.77 NOS1 GHSR GHRL
4 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.66 DRD2 ADRA1D
5 positive regulation of cAMP-mediated signaling GO:0043950 9.66 SCT GIP
6 oxidative demethylation GO:0070989 9.65 CYP3A4 CYP2D6
7 neurotransmitter biosynthetic process GO:0042136 9.65 TH NOS1
8 response to acidic pH GO:0010447 9.65 SST GIP
9 positive regulation of growth GO:0045927 9.64 GHSR GHRL
10 synaptic transmission, dopaminergic GO:0001963 9.64 TH DRD2
11 negative regulation of appetite GO:0032099 9.63 GHSR CCK
12 response to nicotine GO:0035094 9.63 TH HMOX1 DRD2
13 response to drug GO:0042493 9.63 TH SST HMOX1 GIP DRD2 ABCB1
14 adult feeding behavior GO:0008343 9.62 GHSR GHRL
15 positive regulation of growth hormone secretion GO:0060124 9.62 GHRL DRD2
16 hyaloid vascular plexus regression GO:1990384 9.61 TH DRD2
17 heterocycle metabolic process GO:0046483 9.61 CYP3A4 CYP2D6
18 positive regulation of multicellular organism growth GO:0040018 9.61 GHSR GHRL DRD2
19 drug catabolic process GO:0042737 9.59 CYP3A4 CYP2D6
20 growth hormone secretion GO:0030252 9.58 GHSR GHRL
21 monoterpenoid metabolic process GO:0016098 9.58 CYP3A4 CYP2D6
22 negative regulation of insulin secretion GO:0046676 9.58 GHSR GHRL DRD2
23 positive regulation of eating behavior GO:1904000 9.56 GHSR GHRL
24 response to nutrient levels GO:0031667 9.56 TH SCT GIP GHRL
25 regulation of transmission of nerve impulse GO:0051969 9.55 GHSR GHRL
26 positive regulation of appetite GO:0032100 9.54 GHSR GHRL
27 regulation of gastric motility GO:1905333 9.52 GHSR GHRL
28 positive regulation of small intestine smooth muscle contraction GO:1904349 9.51 GHSR GHRL
29 exogenous drug catabolic process GO:0042738 9.5 NOS1 CYP3A4 CYP2D6
30 isoquinoline alkaloid metabolic process GO:0033076 9.49 TH CYP2D6
31 alkaloid catabolic process GO:0009822 9.48 CYP3A4 CYP2D6
32 positive regulation of small intestinal transit GO:0120058 9.37 GHSR GHRL
33 G protein-coupled receptor signaling pathway GO:0007186 9.36 SST SCT MLNR MLN GIP GHSR
34 postsynaptic modulation of chemical synaptic transmission GO:0099170 9.13 GHSR GHRL DRD2

Molecular functions related to Gastroparesis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.8 TH NOS1 HMOX1 CYP3A4 CYP2D6
2 monooxygenase activity GO:0004497 9.5 TH CYP3A4 CYP2D6
3 hormone binding GO:0042562 9.37 MLNR GHSR
4 dopamine binding GO:0035240 9.26 TH DRD2
5 heme binding GO:0020037 9.26 NOS1 HMOX1 CYP3A4 CYP2D6
6 hormone activity GO:0005179 9.17 SST SCT MLN GIP GHRL GAST
7 tetrahydrobiopterin binding GO:0034617 9.16 TH NOS1

Sources for Gastroparesis

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
69 Tocris
71 UMLS via Orphanet
Loading form....